组会讲课人员:陈星雅
Selection of Fluorescent, Bioluminescent, and Radioactive Tracers to Accurately Reflect Extracellular Vesicle Biodistributionin Vivo
集成微流控sers平台可对早期黑色素瘤的血清细胞外囊泡进行敏感表型分析
主讲人:陈星雅
Biosensors and bioelectronics |Volume 126, 1 February 2019, Pages 178-186| https://doi.org/10.1016/j.bios.2018.10.044
Abstract:
Precise detection of early melanomas is essential as the stage of disease guides treatment options. One growing field that may facilitate the advancement of early melanoma detection, is achieved through profiling serum extracellular vesicles (EVs) using sensitive nanotechnology. As a proof of principle, using a detection platform that combines a microfluidic device and surfaceenhanced Raman spectroscopy (SERS), the expression profiles of 4 protein biomarkers in serum EVs (termed as “EV SERS signatures”) derived from 20 early stage melanoma patients (including in situ melanoma) and 21 healthy participants are multiplexed. Significantly higher signal intensities of selected protein biomarkers are observed in serum EVs from melanoma patients compared with healthy participants, with mean fold-changes ranging from 3.7 to 4.2. It is demonstrated that the EV SERS signatures can accurately separate melanoma patients and healthy individuals, with an area under the curve of 0.95. Thus, with further development, this ultra-sensitive detection platform, combined with the panel of melanoma-associated biomarkers, has the ability to differentiate early stage melanoma patients from healthy participants.
.
摘要:
准确检测早期黑色素瘤是至关重要的,因为疾病的阶段指导治疗方案。利用敏感纳米技术分析血清细胞外囊泡(ev),可以促进黑色素瘤早期检测的发展,这是一个日益增长的领域。作为原理的证明,使用结合微流控装置和表面增强拉曼光谱(SERS)的检测平台,对来自20名早期黑色素瘤患者(包括原位黑色素瘤)和21名健康参与者的血清EV中4种蛋白生物标志物的表达谱(称为“EV SERS标签”)进行了多路复用。与健康参与者相比,在黑色素瘤患者的血清ev中观察到明显更高的选定蛋白生物标志物的信号强度,平均折射率变化范围为3.7 – 4.2。研究表明,EV SERS标签能够准确地将黑色素瘤患者和健康个体区分开来,曲线下面积为0.95.因此,随着进一步的发展,这个超敏感的检测平台,结合黑色素瘤相关的生物标志物面板,有能力区分早期黑色素瘤患者和健康参与者。